Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum‐pemetrexed for T790M mutation‐positive advanced non–small cell lung cancer
Vassiliki A. Papadimitrakopoulou , Ji‐Youn Han , Myung‐Ju Ahn , Suresh S. Ramalingam
Cancer 126 ( 2) 373 -380
83
2020
A new ETV6-NTRK3 cell line model reveals MALAT1 as a novel therapeutic target - a short report
Suning Chen , Stefan Nagel , Bjoern Schneider , Haiping Dai
Cellular Oncology 41 ( 1) 93 -101
9
2018
Refining the sensitivity of plasma cell-free DNA (cfDNA) genotyping by controlling for plasma tumor content.
Catherine Meador , Yuebi Hu , James Chih-Hsin Yang , Tony Mok
Journal of Clinical Oncology 36 ( 15_suppl) 9071 -9071
4
2018
Guide to detecting epidermal growth factor receptor ( EGFR ) mutations in ctDNA of patients with advanced non-small-cell lung cancer
Nicola Normanno , Marc G. Denis , Kenneth S. Thress , Marianne Ratcliffe
Oncotarget 8 ( 7) 12501 -12516
130
2017
Abstract LB-123: Analysis of cell-free plasma DNA (cfDNA) identifies 3 molecular subtypes of acquired resistance to AZD9291, a novel EGFR tyrosine kinase inhibitor (TKI), in patients (pts) with advanced lung cancer
Geoffrey R. Oxnard , Kenneth S. Thress , Cloud P. Paweletz , Enriqueta Felip
Cancer Research 75
2015
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.
Geoffrey R. Oxnard , Yuebi Hu , Kathryn F. Mileham , Hatim Husain
JAMA Oncology 4 ( 11) 1527 -1534
495
2018
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
Catherine A. Eberlein , Daniel Stetson , Aleksandra A. Markovets , Katherine J. Al-Kadhimi
Cancer Research 75 ( 12) 2489 -2500
285
2015
A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Ian W. Flinn , Nancy L. Bartlett , Kristie A. Blum , Kirit M. Ardeshna
European Journal of Cancer 54 11 -17
53
2016
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
Geoffrey R. Oxnard , Kenneth S. Thress , Ryan S. Alden , Rachael Lawrance
Journal of Clinical Oncology 34 ( 28) 3375 -3382
814
2016
Elucidation of PARP inhibitor activity in BRCAwt recurrent ovarian cancer by hrr mutational gene profile analysis.
Mansoor Raza Mirza , Bin Feng , Ming Shan , Kaiming Sun
Journal of Clinical Oncology 37 5568 -5568
2019
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291
Kenneth S. Thress , Roz Brant , T. Hedley Carr , Simon Dearden
Lung Cancer 90 ( 3) 509 -515
480
2015
EGFR T790M mutation testing within the osimertinib AURA Phase I study
Simon Dearden , Helen Brown , Suzanne Jenkins , Kenneth S. Thress
Lung Cancer 109 9 -13
17
2017
Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System.
Margaret H. Veldman-Jones , Zhongwu Lai , Mark Wappett , Chris G. Harbron
Clinical Cancer Research 21 ( 10) 2367 -2378
62
2015
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
Peter Ballard , James W.T. Yates , Zhenfan Yang , Dong-Wan Kim
Clinical Cancer Research 22 ( 20) 5130 -5140
554
2016
Abstract B105: Characterization of the activity of AZD9291 in patients (pts) with T790M ‘negative’ advanced non-small cell lung cancer (aNSCLC)
Pasi A. Jänne , Enriqueta Felip , Dong-Wan Kim , Thomas John
Molecular Cancer Therapeutics 14
2015
Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance
Carina Heydt , Sebastian Michels , Kenneth S. Thress , Sven Bergner
Oncotarget 9 ( 20) 15418 -15434
17
2018
Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial.
Kenneth S. Thress , Vivien Jacobs , Helen K. Angell , James Chih-Hsin Yang
Journal of Thoracic Oncology 12 ( 10) 1588 -1594
13
2017
Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
Julian Downward , Aleksandra Markovets , Elza C de Bruin , Kenneth S Thress
Nature Communications 12 ( 1) 1780 -1780
2021
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
Kenneth S Thress , Cloud P Paweletz , Enriqueta Felip , Byoung Chul Cho
Nature Medicine 21 ( 6) 560 -562
1,373
2015
EGFR mutation analysis for prospective patient selection in two phase II registration studies of osimertinib
Suzanne Jenkins , James Chih-Hsin Yang , Pasi A Jänne , Kenneth S Thress
Journal of Thoracic Oncology 12 ( 8) 1247 -1256
69
2017